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ABSTRACT 23 
Porphyromonas gingivalis (P. gingivalis) is one of the several important bacterial pathogens 24 
associated with the sporadic Alzheimer’s disease (AD). Different serotypes are either 25 
capsulated or are non-capsulated. It has been demonstrated that P. gingivalis (non-capsulated) 26 
can reproduce the neurodegenerative AD-like changes in vitro, and a capsular P. gingivalis 27 
(strain W83) could reproduce the cardinal hallmark lesions of AD in a wild-type mouse model. 28 
All P. gingivalis forms express proteolytically active proteases that enable cleavage of the 29 
amyloid precursor protein (APP) and tau resulting in the formation of amyloid-beta and 30 
neurofibrillary tangles (NFTs). Tau is an established substrate for gingipains, which can cleave 31 
tau into various peptides. Some of the P. gingivalis fragmented tau protein peptides contain 32 
“VQIINK” and “VQIVYK” hexapeptide motifs which map to the flanking regions of the 33 
microtubule binding domains and are also found in paired helical filaments that form NFTs. P. 34 
gingivalis can induce peripheral inflammation in periodontitis and can also initiate signaling 35 
pathways that activate kinases, which in turn, phosphorylate neuronal tau. Periodontal disease 36 
related inflammation has metabolic implications for an individual’s peripheral and brain health 37 
as patients suffering from generalized periodontitis often have related co-morbidities and are 38 
“at risk” of developing AD. The aim here is to discuss the role of P. gingivalis behind such 39 
associations with the backdrop of huge efforts to test P. gingivalis virulence factors clinically 40 
(GAIN Trial: Phase 2/3 Study of COR388 in Subjects with AD) with inhibitors, which may 41 
lead to an intervention by reducing the pathogenic bacterial load. 42 
 43 
KEYWORDS: Alzheimer’s disease, gingipains, Porphyromonas gingivalis, periodontal 44 
disease  45 
 46 
 47 
 48 
 49 
 50 
 51 
Alzheimer’s disease and its association with periodontal disease 52 
3 
 
 
 The presence of extra neuronal amyloid (Aβ) plaques and intra-neuronal 53 
neurofibrillary tangles (NFTs) in the brain, together with defined clinical signs of cognitive 54 
deficit, form the basis of the diagnostic criteria for AD at autopsy [1, 2]. The origins and the 55 
roles of Aβ plaques and NFTs appear quite distinct but together they lead to neurodegeneration. 56 
The hippocampus contains abundant intra-neuronal NFTs composed of abnormally 57 
phosphorylated tau protein. According to Braak staging of AD; the NFTs spread in the brain 58 
in a defined distribution, which allows correlations to be made with the clinical stages [3]. 59 
Early involvement of tau pathology has been described in the subcortical nuclei such as the 60 
locus coeruleus and the pons anatomical areas of the brainstem [3, 4]. This anatomical site of 61 
the brain releases norepinephrine in response to emotional and stress related factors. The locus 62 
coeruleus also controls the attention and alertness of an individual, so any adverse change in 63 
its homeostasis could affect behaviour and mood. Notably, the trigeminal ganglion is located 64 
adjacent to the locus coeruleus of the brainstem [5]. It follows that the brainstem and the 65 
periodontium communicate via the trigeminal nerve because tooth related pain is registered in 66 
the brain. In support, the neurons of the trigeminal nerve are known to be distributed within the 67 
periodontal ligament [13]. This provides an important link between periodontitis and the areas 68 
of the brain that are affected early in the progression of AD pathology. 69 
 Periodontitis is a chronic inflammatory disease which damages the tooth supporting 70 
tissues i.e. gingivae, periodontal ligament and alveolar bone [6, 7]. Bacteria which can instigate 71 
changes in a normally symbiotic microbial community to a dysbiotic state are termed ‘keystone 72 
pathogens’. Porphyromonas gingivalis (P. gingivalis), is a Gram negative coccobacillus 73 
shaped bacterium which has long been established as a keystone pathogen for periodontitis [6, 74 
7]. This oral commensal becomes pathogenic and can exert its virulence via its endo/exotoxins 75 
(surface membrane lipopolysaccharide or LPS, and gingipains) and capsular polysaccharides 76 
that allow this bacterium to induce chemokine paralysis of the host and evade immune 77 
4 
 
 
recognition, even in low abundance. The compromised host innate and adaptive immune 78 
responses may be inadequate to control the inflammophilic microbiota and paradoxically, can 79 
contribute to connective tissue damage and inflammatory bone loss [8]. Oral microbes can 80 
enter the systemic circulation during transient episodes of bacteraemia which can occur with 81 
daily oral hygiene activities and dental interventions [9]. Periodontal pathogens including P. 82 
gingivalis have been detected at disparate sites such as the atherosclerotic plaque [10] and AD 83 
brains [11, 12]. Pertinent to this, it has been demonstrated in AD transgenic mice that extraction 84 
of molar teeth generated release of the cytotoxic Aβ, and triggered neurodegeneration in the 85 
locus coeruleus via its connection with the trigeminal nerve pathway connecting the 86 
periodontium [13]. This may provide an explanation for the underappreciated concepts such as 87 
missing molar teeth and their contribution to neuronal loss in AD [14-17]. 88 
This review will cover some salient aspects of P. gingivalis, the keystone periodontal 89 
disease pathogen, that makes this bacterium “important” as a strong risk factor for developing 90 
AD pathophysiology with an emphasis on the pathways that produce hallmark pathology. This 91 
is plausible as we now have a better understanding of the P. gingivalis secreted exotoxin known 92 
as gingipains that expresses cathepsin B proteolytic enzymatic activity, which enables cleavage 93 
of amyloid precursor protein (APP), to form Aβ plaques. Furthermore, gingipains   has the 94 
potential to disturb tau homeostasis by hyperphosphorylating serine and threonine residues via 95 
inflammatory signaling that activate glycogen synthase kinase-3beta (GSK-3β). In addition, 96 
proteolytically active gingipains can hydrolyse tau protein to release fragments [12] with the 97 
“VQIINK” and “VQIVYK” hexapeptide motifs that are present in the paired helical filaments 98 
that constitute the NFT lesion. These are significant recent leaps in scientific advances in order 99 
to understand the risk factor involvement of periodontal disease with the development of AD.  100 
 101 
What makes P. gingivalis a risk factor for AD?    102 
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       Inflammation is widely thought to contribute to the cognitive decline in AD [18]. However, 103 
peripheral episodes of inflammation and/or microbial access to the brain and their impact on 104 
triggering cerebral inflammation have largely been ignored. The pathways for microbial access 105 
to the brain are many [19] including a leaky blood-brain barrier (BBB). P. gingivalis can trigger 106 
the peripheral and cerebral immune responses. Periodontitis can exert its influence indirectly 107 
by sustaining peripheral inflammation. This together with defective susceptibility genes that 108 
normally help with clearance of waste from the brain, can prime microglial cells into a pro-109 
inflammatory phenotype [20]. 110 
Other major risk factors for AD are comorbid in the presence of the Apolipoprotein E, allele 111 
4 (APOE є4) susceptibility gene inheritance [21]. One effect is related to the decline of cerebral 112 
blood flow across the lifespan of an individual during normal aging but this effect is greater in 113 
subjects with APOE є4 susceptibility gene inheritance [22]. Lack of an adequate systemic 114 
blood flow to the brain in older individuals and those suffering from dementia harbouring the 115 
APOE є4 susceptibility gene can precipitate cerebrovascular pathologies such as stroke, small 116 
vessel arteriosclerosis and others [23-25]. In addition, middle aged hypertension and diabetes 117 
also increase the risk of AD [26], this risk may be heightened in the presence of P. gingivalis 118 
oral infection due to severe periodontitis, which has metabolic implications for an individual’s 119 
peripheral and brain health [27, 28]. Meta-analysis has shown that there is a 250% higher risk 120 
for incident dementia in persons with both APOE є4 inheritance and diabetes than those 121 
without; and a 35% higher risk for those with APOE є4 alone [29]. Figure 1 illustrates the 122 
shared risk factors of periodontal disease and AD, which includes the genetic components, 123 
comorbidities and environmental factors. This further supports the plausibility of P. gingivalis 124 
as a risk factor in itself. 125 
In addition, the BBB function becomes inadequate during normal aging and in cognitively 126 
impaired individuals carrying the APOE є4 genetic susceptibility [30-32]. A disrupted BBB 127 
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during aging and dementia [33] can potentially facilitate the passage of P. gingivalis from the 128 
systemic circulation into the brain. The scientific rationale for this statement comes from 129 
observations made from P. gingivalis mono-infected apolipoprotein null mice models of 130 
periodontitis for AD pathophysiology. P. gingivalis from the oral cavity accessed the brain and 131 
the BBB appeared significantly damaged [34-36]. A mechanistic pathway for bacterial entry 132 
into the brain is suggested to be via proteolytically active gingipains (the extracellular cysteine 133 
proteinases of P. gingivalis strain W83) breaking down the epithelial transmembrane proteins, 134 
E-cadherin, β1 integrin and occludin, thereby disrupting the tight junctions between capillary 135 
endothelial cells. This increases the permeability of the BBB [37]; and in addition, systemic 136 
proinflammatory cytokines also can potentially disrupt the BBB [38]. It is assumed that when 137 
tight junction integrity is sufficiently disturbed, passage of bacteria into the brain is likely to 138 
take place. In supporting the adverse effects of the cytokine on the BBB integrity, Vernal et al. 139 
[39] have reported that capsular serotype K1 and K2 P. gingivalis strains outside the central 140 
nervous system induce an enhanced secretion of pro-inflammatory interleukin cytokines (IL)-141 
1β, IL-4, IL-6, IL-10, IL-17, interferon (IFN)-γ, and tumor necrosis factor (TNF)-α in 142 
macrophages and dendritic cells, implying capsular P. gingivalis strains have the armoury for 143 
potentiating BBB permeability through cytokine liberation. Encapsulated bacterial infections 144 
for example, P. gingivalis W83, harbours an additional virulence factor in the form of the 145 
capsular polysaccharide or A-lipopolysaccharide (A-LPS) which is different from the 146 
lipopolysaccharide (LPS) of the outer membrane of non-encapsulated bacteria for example P. 147 
gingivalis (strain ATCC 33277) [see 40]. The A-LPS in the capsulated P. gingivalis (W83) 148 
plays a vital role in this bacterium’s virulence development by inducing proinflammatory 149 
cytokine paralysis [41] as it is connected to the post-translational additions of Arg-gingipains 150 
that make the bacterium more virulent [42, 43].  151 
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 Therefore, a person harbouring capsular forms of P. gingivalis could have a higher 152 
risk of developing AD, compared with those who carry the non-capsulated bacterium. This 153 
may be one reason why not all individuals who suffer from periodontal disease also manifest 154 
AD [15, 43]. Prevalence studies among the Dutch population identified K6 serotype (capsular) 155 
as the most prevalent (23%) [44], whilst, the K5 serotype (capsular) was frequently observed 156 
in 25% of the subgingival isolates examined from Indonesian AD subjects [45].  157 
 158 
P. gingivalis gingipains, the most critical virulence factor  159 
P. gingivalis produces gingipains R, (RgpA, RgpB) and gingipain K, (Kgp). Gingipains 160 
are classified as collagenases and trypsin-like cysteine proteinases [46], and are secreted by all 161 
strains (with/without capsule) of P. gingivalis [47, 48]. Together they degrade a variety of 162 
proteins involved in the immune response [49-52]. Here, our interest is in the trypsin-like 163 
cysteine proteinases, secreted by all strains of P. gingivalis [47, 48], which specifically cleave 164 
peptides at Arginine-Xaa and Lysine-Xaa (Xaa = any amino acid) from the C-terminus. The 165 
Arg-specific proteolytic activity is encoded by rgpA/B genes while the Lys-specific activity is 166 
encoded by the kgp gene. Rgp and Kgp are enzymes responsible for the trypsin-like activity 167 
associated with P. gingivalis and hence are important in the context of tau NFTs [47].  168 
 Recent studies have postulated that tau protein (associated with microtubules) and 169 
actin are substrates of Kgp gingipain [13, 53]. Neither Lys-gingipain nor Arg-gingipain are 170 
inhibited by internal protease inhibitors such as cystatins and α-antichymotrypsin and are 171 
therefore, able to diffuse into host tissues. Furthermore, gingipains are thermally stable from 172 
0-45ºC and over a range of pH fluctuations 5.5 to 10.5 [54]. It is not surprising in view of the 173 
sensitivity of tau to trypsin [55], that it is a potential substrate for gingipains in vivo [12]. This 174 
exciting finding is potentially a major breakthrough for therapy based on low molecular weight 175 
small-molecules designed to block the toxic effects of the different types of gingipains secreted 176 
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by P. gingivalis, which are currently in Phase 3 clinical trials. An aspect of the gingipains 177 
inhibitor COR388 based therapy is provided elsewhere [56]. 178 
 179 
P. gingivalis and its association with neurodegeneration 180 
AD is a neurodegenerative disease and hence neuronal loss is pivotal to the disease 181 
process. To this end, Goto et al. [13], performed surgical extractions of molar teeth in their 182 
triple transgenic AD (3xTg-AD) mice and uncovered a neurodegenerative pathway involving 183 
the trigeminal distribution within the periodontal ligament to the locus coeruleus. From the 184 
locus coeruleus, the tau pathology subsequently spreads to the hippocampus. The loss of molar 185 
teeth in AD patients is predominantly associated with periodontitis and in general, tooth loss 186 
has been linked to a higher risk of AD [14-17]. P. gingivalis (ATCC 33277) has been reported 187 
to cause AD-like neurodegeneration in infected neurons derived from induced pluripotent stem 188 
cells (iPSC) in an in-vitro culture system with persistent expression of active gingipains, 189 
resulting in a 25% loss of neurons over three days [57]. The differentiated iPSC neurons can 190 
be maintained for months and offer a time efficient in vitro analysis of measuring neuronal 191 
degeneration compared to examining the years of AD-related neurodegenerative processes in 192 
humans. Furthermore, P. gingivalis can invade and survive within neurons and generate intra-193 
neuronal gingipains, which are proteolytically active, implying the plausibility of direct 194 
neurodegeneration associated with NFT lesion formation in AD taking place [57].  195 
 196 
P. gingivalis infection and periodontitis are linked to deteriorating memory  197 
The first interventional study with human AD subjects was carried out by Rolim et al. [58] in 198 
which they demonstrated a beneficial outcome of dental treatment in AD subjects. The reported 199 
benefit to the patients with mild AD was in terms of reduced orofacial pain and an improvement 200 
in the mandibular function and periodontal indices. These improvements were maintained until 201 
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the last evaluation after six months, and were followed by a reduction in the functional 202 
cognitive impairment. Several proof of concept studies carried out in either mice with 203 
experimentally induced periodontal disease with an oral infection with P. gingivalis, or with 204 
the introduction of its LPS have indicated that inflammatory signaling pathways contribute to 205 
a clinical phenotype in which impaired learning and memory is observed [59-61]. The 206 
inflammatory basis of deteriorating memory is upheld by the results from clinical trials in 207 
human AD subjects with periodontitis [62]. For a more comprehensive overview, see Singhrao 208 
and Olsen [63].  209 
 210 
P. gingivalis and its association with AD diagnostic lesion formation 211 
P. gingivalis has the potential to induce inflammation peripherally due to periodontitis [64] and 212 
subsequently in the brain via its intracerebral entry or entry of its virulence factors (LPS and 213 
gingipains) [65-67]. Gingipains released by P. gingivalis which have similar APP-cleaving 214 
action as cathepsin B (of the host) [12], interact with the APP signaling pathways (amyloid 215 
cascade) to release Aβ [60]. In this process, gingipains together with LPS can proteolytically 216 
activate kinases such as GSK-3β which subsequently phosphorylates neuronal tau [57, 66].  217 
 Up until now, abnormally phosphorylated tau protein has not featured negatively in 218 
the pathophysiology of periodontal disease per se. However, Adamowicz et al. [68] implicated 219 
the role of GSK-3β in bacterial-induced periodontitis because its inhibition rescued bone loss. 220 
Thus, GSK-3β may be influencing phosphorylation of brain tau via immune responses 221 
mediated by P. gingivalis, in the Ilievski et al. [66] and Haditsch et al. [57] studies. The 222 
introduction of phosphorylated tau is an important point, especially since the intraneuronal 223 
cytoskeletal alterations precede the formation of amyloid in AD locus coeruleus [69]. This is 224 
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interesting when compared with the Tg mouse tooth extractions where cytotoxic Aβ, triggered 225 
neurodegeneration in the same brain region (i.e locus coeruleus) [13]. 226 
 227 
P. gingivalis and the Aβ plaque lesion 228 
The extra neuronal AD plaque is composed of Aβ forming the basis of the “Amyloid 229 
Hypothesis” [70]. Aβ is a cleavage product of APP, which is seen in internal vesicular 230 
membranes, including the Golgi apparatus and endosomes [63, 71]. Hence, a direct 231 
extracellular deposition of soluble/insoluble Aβ as well as an intra-cellular processed soluble 232 
Aβ [63, 72, 73] both contribute to the extracellular fibrillary/insoluble (diffuse and neuritic) 233 
plaques in AD brains. The APP proteolytic cleavage is completed by the proteolytically active 234 
secretase enzymes (α-, β- and γ-secretases). In rare familial AD cases however, there is a 235 
mutant form of APP (Swedish double mutation APP K67ØM, N671L) which has a double 236 
mutation at the start of the cleavage site of the beta-site of APP cleaving enzyme 1 (BACE -1). 237 
BACE-1 has been shown to bind this mutated site with much higher affinity than the wtAPP 238 
and thus cleaves to form Aβ much more readily [73]. Notably, the enzyme cathepsin B, which 239 
is expressed in secretory vesicles within neurons, is shown, conversely, to bind with high 240 
affinity to wtAPP (and not to the Swedish mutant APP) and has been suggested as a likely 241 
candidate for production of Aβ in the sporadic form of AD [73]. As described earlier, 242 
gingipains, the exotoxin of P. gingivalis, also has cathepsin B-like activity [12] and may act to 243 
cleave APP [73]. Wu et al. [60] demonstrated the host related cathepsin B to interact with APP 244 
to liberate Aβ. In order to determine the intracellular processing of APP by P. gingivalis-LPS 245 
(Pg-LPS), Wu et al. [60] challenged the wt-APP mice and observed that the host’s cathepsin 246 
B, together with inflammatory mediators (IL-1β), directed APP proteolysis to release soluble 247 
amyloid which they interpreted to be Aβ42 species. Why the host’s cathepsin B activity and 248 
not the P. gingivalis cathepsin B-like activity are acting here is because we postulate that the 249 
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highly purified Pg-LPS used by Wu et al. [60] is likely to have been denatured by the 250 
purification process leaving the LPS activity intact. Following P. gingivalis infections, an 251 
increase in peripheral Aβ1-40/42 accumulation within periodontal tissues have been shown in 252 
mice models and in the human gingival tissues and human serum thereby potentially adding to 253 
the Aβ pool in the AD brain [74-76]. To this end, Zeng et al. [77] identified advanced glycation 254 
end products (AGE) as a likely receptor for Aβ1-40/42 in cerebral endothelial cells implying AGE 255 
products-receptor are a plausible mediator of cerebrovascular-related Aβ accumulation after P. 256 
gingivalis infection in their mouse model. This supports the hypothesis that patients harboring 257 
the generalized form of periodontal disease may be “at risk” of developing AD via multiple 258 
pathways. Key evaluations of prospective and retrospective population based data have shown 259 
that chronic periodontal disease that exists for longer than ten years results in a doubling of the 260 
risk for the sporadic form of AD [78-80]. Putting this information in perspective, the 10 year 261 
lag allows amyloid-beta (Aβ) plaques to reach a plateau in the human host and this is when the 262 
host begins to indicate the earliest stage (mild cognitive impairment or MCI or prodromal) of 263 
AD. Following this stage, the pathological cascade of progressive AD would take over. This is 264 
interesting because the pieces of the jig-saw puzzle that form the picture of AD is beginning to 265 
emerge from reported scientific observations regarding the co-morbidity between periodontal 266 
disease and AD in some patients. Periodontal disease can start at any age and the time it takes 267 
to become chronic may vary from individual to individual. If that individual was vulnerable to 268 
manifesting AD later in life, it should be possible to predict the risk age of that individual from 269 
the time that their periodontitis became chronic. Taken together, an early detection of disease 270 
means patients may benefit from an earlier medical intervention. 271 
 272 
“Gingipains” interaction with tau protein: what does this mean for neurofibrillary 273 
tangles? 274 
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The NFTs represent hyperphosphorylated tau proteins binding to microtubules. 275 
Hyperphosphorylation of microtubules is abnormal because normal tau becomes insoluble and 276 
subsequently aggregates. This also causes the collapse of microtubules into non–membrane-277 
bound masses of abnormal paired helical and straight filaments (PHF) which are found in the 278 
perinuclear cytoplasm of specific neurons. These constitute NFTs [81, 82]. Understanding the 279 
formation of the NFT lesion due to bacterial interaction is important as autopsied brains from 280 
AD cases have confirmed the presence of the following microbes (Actinomycetes [83, 84], P. 281 
gingivalis [12, 56], Helicobacter pylori,  282 
and Chlamydia pneumoniae [85], Herpes Simplex type 1 virus (HSV1) [86], select species of 283 
oral/non-oral spirochaetes [87], and select fungi [88]). Furthermore it has been reported that 284 
Bacteroides species such as P. gingivalis are more virulent as a result of mixed infection with 285 
the Actinobacillus actinomycetemcomitans bacteria facilitating their movement between 286 
different organs [89, 90].  287 
Dominy et al. [12] demonstrated tau protein as a substrate for P. gingivalis protease 288 
gingipains and as a consequence, the resultant tau protein fragments can be released into the 289 
brain’s parenchymal tissues. Depending on their size (Table 1), these extracellular 290 
phosphorylated tau fragments may be directly toxic to other neurons. The smaller sized 291 
phosphorylated tau fragments may be taken up by other connecting cells at the synaptic clefts 292 
during neurotransmitter uptake, thereby facilitating its spread from neuron to neuron and 293 
subsequently spreading pathology.  294 
 295 
Tau cleavage by gingipains and its involvement in paired helical filaments 296 
P. gingivalis protease gingipains have been demonstrated to co-localize with 297 
microtubules and paired helical filaments (PHF) constituting NFTs in AD brains [12]. As 298 
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mentioned earlier, tau protein can be hydrolyzed by gingipains into several fragments both 299 
from the N and C termini [12]. Six out of several fragments have “VQIINK” and “VQIVYK” 300 
hexapeptide common motifs that bind to the microtubule binding domains flanking regions, 301 
which support the microtubule filaments (Figure 2, Table 1). This implies that six of the several 302 
tau fragments released by gingipains are from the pivotal sites of the functional microtubules 303 
and agrees with previously reported observations [12]. Furthermore, PHF filaments also have 304 
VQIINK and VQIVYK hexapeptide signatures [see ref 91].  Therefore, tau cleavage at 305 
VQIINK and VQIVYK hexapeptides from the regions of considerable functional significance 306 
to microtubules “would collapse” the intact microtubule assembly with the said hexapeptide 307 
peptide amino acid signatures within tau and PHFs, constituting the NFT lesions [12, 91].  308 
Further research is needed to clarify the role of gingipains fragmented tau peptides in the 309 
pathogenesis of AD. 310 
 311 
P. gingivalis phosphorylates tau protein 312 
Tau protein binds to microtubules and is prone to hyperphosphorylation. 313 
Hyperphosphorylation of tau protein signifies a pathological change, which precedes NFT 314 
formation. It is believed that phosphorylated tau proteins accumulate within neurons prior to 315 
NFT formation [92]. What causes this shift between bound to free pathological tau in neuronal 316 
cells is not clear, but P. gingivalis enzyme activity hydrolysing this protein as shown by 317 
Dominy et al. [12] cannot be ruled out. Haditsch et al. [57] demonstrated an increased tau 318 
phosphorylation at two residues (enhanced tau phosphorylation at Thr231and at Ser396) 319 
following P. gingivalis infection in an iPSC differentiated neuronal cell culture model. 320 
Furthermore, the capsular serotype K1 P. gingivalis W83 strain has been shown to have the 321 
potential to contribute to tau phosphorylation at Ser396 in the in vivo wild-type mouse model 322 
[66]. These are accepted phosphorylation sites as evaluated previously by Hanger et al. [93]. 323 
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However, which kinase may be responsible for phosphorylating Ser396 and Thr231 following 324 
P. gingivalis infection is not clear, but glycogen synthase kinases-3 beta (GSK-3β) is a strong 325 
candidate [93]. Recently Liu et al. [94] observed in their gingivalis-infected microglial cell 326 
model that phosphoinositide 3-kinase (Pi3K)/ protein kinase B1 (Akt) and mitogen-activated 327 
protein kinase/extracellular signal-regulated kinase (ERK) kinase/ERK pathways were 328 
activated. Our study in which purified P. gingivalis LPS (Pg-LPS) was applied to a 329 
neuroblastoma cell line, in vitro cell model also demonstrated that the PI3K/AKT pathways 330 
were activated [95]. In addition, Bahar and Singhrao [95] showed GSK-3β and forkhead box 331 
class O1 (FOXO1) and NF-kB mRNA expression was also up-regulated and that this was 332 
dependent on the MyD88 pathway [95]. The importance here is that GSK-3β is one of the 333 
enzymes that can phosphorylate tau residues Ser396 and Thr231 [93] and its activation 334 
implicates the onset of inflammatory signaling [95] that are known to be involved in AD 335 
pathophysiology [96, 97]. This implies that P. gingivalis infection plays an important role in 336 
the infected cells where balance of inflammation and inflammation responsive kinases (e.g. 337 
GSK-3β) are tipped in favour of phosphorylation, NFT lesion formation and subsequent 338 
pathophysiology of AD. 339 
 340 
Conclusions 341 
This review has applied a pathobiome concept in substantiating the link between P. 342 
gingivalis infection and AD lesions. It is clear from the human and proof of concept studies in 343 
animal models that whole bacteria and their constituent endo/exotoxins enter the central 344 
nervous system. In-situ, this bacterium has a range of enzymes that are shown to interact with 345 
APP and tau, deregulating their structure and intracellular processing, with resultant formation 346 
of Aβ and PHF respectively. We appreciate that other bacterial, fungal or viral pathogens 347 
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implicated in AD may follow different pathways towards AD pathophysiology compared to 348 
those described here for P. gingivalis. 349 
It is evident that P. gingivalis is a potentially significant etiological agent for AD 350 
pathophysiology. Whilst generalised periodontitis develops around middle age, the sporadic 351 
form of AD is of much later onset. The lag phase between the two comorbidities could provide 352 
us with a mechanistic association between the two diseases and a window of opportunity to 353 
inhibit the toxic insults of gingipains in patients with periodontitis, and its downstream 354 
inflammatory effects such as systemic inflammation contributing to the risk of developing AD 355 
or increasing the severity of dementia by hyperphosphorylating tau. Hence, the clinical “GAIN 356 
Trial”: Phase 2/3 Study of COR388 in Subjects with Alzheimer's disease. (ClinicalTrials.gov 357 
Identifier: NCT03823404) is key to testing this hypothesis and advancing the adjunctive 358 
management of healthcare landscape in preventing and/or slowing down AD. It is imperative 359 
that the oral health component is included as a modifiable risk factor in AD public health 360 
messages along with other preventative advice such as keeping active, eating healthily and 361 
exercising. 362 
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6*  
MBD-2/3 
305–335 
K298-
K321 
298HVPGGGSVQIVYKPVDLSKVTSK321 
7* 
MBD-2/3 
305–335 
K294-
K317 
294DNIKHVPGGGSVQIVYKPVDLSK317 
8* 
MBD-2/3 
305–335 
K294-
K321 
294DNIKHVPGGGSVQIVYKPVDLSKVTSK321 
9 
C-terminal 
domain 
(368–441) 
R406-
K438 
HLSNVSST414GS416IDMVDSPQLATLADEVSALAK 
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Figure Legends 733 
 734 
 735 
Figure 1: The keystone periodontal pathogen, P. gingivalis (P.g) can enter the bloodstream 736 
during episodes of transient bacteraemia and gain access to the brain via multiple routes 737 
including a leaky blood-brain barrier (BBB). The microbial invasion triggers the cerebral 738 
immune response resulting in neuroinflammation and in the formation of the two diagnostic 739 
lesions of AD.  Periodontitis can exert its influence indirectly by sustaining peripheral 740 
inflammation (blue dotted arrow). This can affect glial cells by priming them into a pro-741 
inflammatory phenotype. In addition, this could also overload and overwhelm the clearing of 742 
toxic neuropeptides from the central nervous system (CNS). The potential causal relationship 743 
of periodontitis and AD is further supported by the shared risk factors.  744 
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Fig 2. Schematic of tau protein and domain organisation to help understand the position of 752 
peptides in Table 1 and the 1-4 microtubule binding domains of Tau to microtubules. 753 
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